ArticleVaccines2014
A Recombinant Raccoon Poxvirus Vaccine Expressing both Yersinia pestis F1 and Truncated V Antigens Protects Animals against Lethal Plague.
Article in Vaccines, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 27 citations in OpenAlex.
- Trial
- An adenoviral-vectored vaccine protects mice against aerosol challenge with Yersinia pestis.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- Field vaccination against CCHFV and Hyalomma tick infestation reduces multiple tick-borne infections in sheep.NPJ vaccines · 2026Article
- Safety and immunogenicity of orally administered poxvirus vectored constructs in the white-footed mouse (Vaccine: X · 2023Article
- Oral Sylvatic Plague Vaccine Does Not Adequately Protect Prairie Dogs (Vector borne and zoonotic diseases (Larchmont, N.Y.) · 2021Article
- Differential plague susceptibility in species and populations of prairie dogs.Ecology and evolution · 2019Article
- Plague vaccine: recent progress and prospects.NPJ vaccines · 2019Review
- Impact of Sylvatic Plague Vaccine on Non-target Small Rodents in Grassland Ecosystems.EcoHealth · 2018Article
- Human case of bubonic plague resulting from the bite of a wild Gunnison's prairie dog during translocation from a plague-endemic area.Zoonoses and public health · 2018Article
- Burrow Dusting or Oral Vaccination Prevents Plague-Associated Prairie Dog Colony Collapse.EcoHealth · 2017Article
- Vaccines for Conservation: Plague, Prairie Dogs & Black-Footed Ferrets as a Case Study.EcoHealth · 2017Article
- Sylvatic Plague Vaccine Partially Protects Prairie Dogs (Cynomys spp.) in Field Trials.EcoHealth · 2017Article
- Article
- Plague Vaccine Development: Current Research and Future Trends.Frontiers in immunology · 2016Review
- Age at Vaccination May Influence Response to Sylvatic Plague Vaccine (SPV) in Gunnison's Prairie Dogs (Cynomys gunnisoni).EcoHealth · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In previous studies, we demonstrated in mice and prairie dogs that simultaneous administration of two recombinant raccoon poxviruses (rRCN) expressing Yersinia pestis antigens (F1 and V307-a truncated version of the V protein) provided superior protection against plague challenge compared to individual single antigen constructs. To reduce costs of vaccine production and facilitate implementation of a sylvatic plague vaccine (SPV) control program for prairie dogs, a dual antigen construct is more desirable. Here we report the construction and characterization of a novel RCN-vectored vaccine that simultaneously expresses both F1 and V307 antigens. This dual antigen vaccine provided similar levels of protection against plague in both mice and prairie dogs as compared to simultaneous administration of the two single antigen constructs and was also shown to protect mice against an F1 negative strain of Y. pestis. The equivalent safety, immunogenicity and efficacy profile of the dual RCN-F1/V307 construct warrants further evaluation in field efficacy studies in sylvatic plague endemic areas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.